Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 2 months ago Source:  Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance… View more
Author(s): Tiziana Claudia Aranzulla Added: 8 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more
Research Area(s) / Expertise: Job title: Director and Physician-in-Chief
Dr Fuster completed his medical degree at Barcelona University in 1967 and then pursued an internship at Hospital Clínic de Barcelona. In 1971, he attended the University of Edinburgh as a research fellow in cardiovascular disease for three years under the tutelage of Desmond Julian and Harold Sheehan. He earned his PhD degree at Edinburgh University with his thesis focussing on platelet factor 4… View more
Author(s): Matthew J Budoff Added: 1 year ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more
Research Area(s) / Expertise:

Cardio-oncology

Atherosclerosis and Hyperlipidemia

Job title: Director, Cardio-Oncology Clinic, Mayo Clinic, Rochester, US
Joerg Herrmann, M.D., is a cardiologist researching how cancer and heart disease interact. Dr. Herrmann's research focuses on cardio-oncology, which studies the potential negative effects of cancer treatments on the circulatory system. Additionally, Dr. Herrmann is very interested in vascular illnesses, particularly the formation of atherosclerotic plaques and their effects. His work also… View more
Author(s): Deborah C Nercolini Added: 9 months ago
Explore the critical role of comprehensive CT angiography analysis in pre-procedural TAVR planning with Dr Deborah C Nercolini.This presentation, part of the Structural Interventions track, delves into the meticulous anatomical assessment that guides optimal TAVR device selection and implantation strategy. Dr Nercolini addresses the essential measurements and anatomical considerations that… View more